Real-World Use of Fecal Microbiota Spores, Live-brpk (Formerly SER-109) in Adults With Recurrent Clostridioides difficile Infection in the United States

被引：0
|
作者：
Akerman, Stuart [1 ]
Gumaste, Ashish [2 ]
Chen, Michael [3 ]
Connor, Lisa [4 ]
von Eynatten, Maximilian [5 ]
De Vries, Jane
Nguyen, Dianne [2 ]
机构：
[1] Digest Hlth Associates Texas, Plano, TX USA
[2] Nestle Hlth Sci, Bridgewater, NJ USA
[3] Nestle Hlth Sci, Dallas, TX USA
[4] Nestle Hlth Sci, Lavallette, NJ USA
[5] Nestle Hlth Sci, Lausanne, Switzerland
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 10S期
关键词：
D O I：
10.14309/01.ajg.0001030496.61161.3c
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S282
引用
收藏
页码：S202 / S202
页数：1
相关论文
共 27 条
  • [21] Outcomes of fecal microbiota transplantation for recurrent Clostridium difficile infection: Real-world experience from a tertiary center
    Chauhan, A.
    Apostolov, R.
    Garg, M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 183 - 183
  • [22] An Open-Label Study (ECOSPOR IV) to Evaluate the Safety, Efficacy and Durability of SER-109, an Investigational Oral Microbiome Therapeutic, in Adults With Recurrent Clostridioides difficile Infection (rCDI)
    Khanna, Sahil
    Feuerstadt, Paul
    Huang, Edward
    Oneto, Caterina
    Pardi, Darrell S.
    Wang, Elaine E.
    De, Ananya
    Brady, Kelly
    Memisoglu, Asli
    Lombardi, David
    Hasson, Brooke
    McGovern, Barbara
    Von Moltke, Lisa
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S96 - S97
  • [23] RESULTS FROM AN OPEN-LABEL STUDY (ECOSPOR IV) TO EVALUATE THE SAFETY AND EFFICACY OF SER-109, AN INVESTIGATIONAL ORAL MICROBIOME THERAPEUTIC, IN ADULTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION (RCDI): A SUBGROUP ANALYSIS
    Pardi, Darrell S.
    Oneto, Caterina
    Berenson, Charles
    Ramesh, Mayur
    Sheikh, Aasim M.
    Phillips, Raymond W.
    Georgetson, Michael J.
    Feuerstadt, Paul
    Wang, Elaine E.
    De, Ananya
    Brady, Kelly
    Lombardi, David A.
    Memisolglu, Asli
    McGovern, Barbara H.
    von Moltke, Lisa
    GASTROENTEROLOGY, 2023, 164 (06) : S699 - S700
  • [24] RBX2660, an Investigational Live Microbiota-based Biotherapeutic, Improves Outcomes of Clostridioides difficile Infection in a Real-World Population: A Retrospective Study of Use Under Enforcement Discretion
    Feuerstadt, Paul
    Harvey, Adam
    Bancke, Lindy
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S92 - S92
  • [25] Improvement in Health-Related Quality of Life in Adults with Recurrent Clostridioides difficile Infection After Fecal Microbiota, Live-js']jslm (RBX2660) Administration by Colonoscopy
    Khanna, Sahil
    McCool-Myers, Megan
    Figueroa, Cindy Umanzor
    Landeira, Margarita
    Wray, Erin
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S166 - S167
  • [26] PUNCH CD3-OLS: A Phase 3 Prospective Observational Cohort Study to Evaluate the Safety and Efficacy of Fecal Microbiota, Live-js']jslm (REBYOTA) in Adults With Recurrent Clostridioides difficile Infection
    Feuerstadt, Paul
    Chopra, Teena
    Knapple, Whitfield
    Van Hise, Nicholas W.
    Dubberke, Erik R.
    Baggott, Brian
    Guthmueller, Beth
    Bancke, Lindy
    Gamborg, Michael
    Steiner, Theodore S.
    Van Handel, Daniel
    Khanna, Sahil
    CLINICAL INFECTIOUS DISEASES, 2024,
  • [27] INTERIM ANALYSIS OF A PHASE 3 OPEN-LABEL STUDY INDICATES SAFETY AND EFFICACY OF RBX2660, AN INVESTIGATIONAL LIVE BIOTHERAPEUTIC, IN A "REAL-WORLD" POPULATION OF PATIENTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION
    Kraft, Colleen
    Khanna, Sahil
    Assi, Maha
    Feuerstadt, Paul
    Harvey, Adam
    Bancke, Lindy
    GASTROENTEROLOGY, 2021, 160 (06) : S573 - S573
123